Anzeige
Mehr »
Login
Mittwoch, 11.12.2024 Börsentäglich über 12.000 News von 683 internationalen Medien
Geheimtipp: Erstmals seit 150 Jahren - Neuer "Rockefeller-Moment" im Rohstoffsektor!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2AN1Z | ISIN: SE0000767188 | Ticker-Symbol: 7AL
Frankfurt
11.12.24
09:07 Uhr
0,022 Euro
-0,002
-8,98 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
ALLIGATOR BIOSCIENCE AB Chart 1 Jahr
5-Tage-Chart
ALLIGATOR BIOSCIENCE AB 5-Tage-Chart
ACCESSWIRE
174 Leser
Artikel bewerten:
(1)

Nomination Committee Appointed in Respect of AGM 2025 in Alligator Bioscience AB

Finanznachrichten News

LUND, SE / ACCESSWIRE / October 31, 2024 / Alligator Bioscience (STO:ATORX) Lund, Sweden, October 31, 2024 - Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces that the Nomination Committee in preparation for the Annual General Meeting (AGM) on May 7, 2025, has been appointed.

Pursuant to the instruction for the Nomination Committee adopted by the AGM in 2019, the Nomination Committee for the Alligator Bioscience AGM 2025 shall consist of four members, representing the three largest shareholders at the last weekday of June, together with the Chairman of the Board. If a shareholder does not exercise its right to appoint a member, entitlement to appoint a member of the Nomination Committee transfers to the shareholder who is the next largest shareholder in terms of voting rights.

Based on the above, the Nomination Committee for the AGM 2025 has been established to consist of the following persons, together representing approximately 44.6 percent of the shares and votes in the company as per the end of June 2024:

  • Bertil Brinck, representing Koncentra Holding AB;

  • Lars Bergkvist, representing Roxette Photo SA;

  • Magnus Pettersson, representing his own shareholding; and

  • Anders Ekblom, Chairman of the Board.

Bertil Brinck has been appointed Chairman of the Nomination Committee.

The task of the Nomination Committee's prior to AGM is to prepare and submit proposals regarding the Chairman of the AGM, the number of Board members elected by the AGM, the Chairman and other Board members elected by the AGM, the fees and other remuneration for each of the Board members elected by the AGM and for members of Board committees, the number of auditors, the auditors, the fee for auditors and election of a Nomination Committee, or alternatively a decision on principles for appointing a Nomination Committee, as well as instructions for the Nomination Committee.

Shareholders wishing to submit proposals or comments to the Nomination Committee may do so via email to ir@alligatorbioscience.com marked "Att. Nomination committee" or by letter to Alligator Bioscience AB, Nomination Committee, Medicon Village, 223 81 Lund, Sweden. To ensure that the proposals can be considered by the Nomination Committee, proposals shall be submitted in due time before the Annual General Meeting, but not later than 31 January 2025.

The Nomination Committee's proposals will be presented in the notice convening the AGM and on the company's website.

For further information, please contact:

Søren Bregenholt, CEO
Email: soren.bregenholt@alligatorbioscience.com
+46 46-540 82 00

The information was submitted for publication, through the agency of the contact person set out above, at 8:15 p.m. CET on October 31, 2024.

About Alligator Bioscience

Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator's portfolio includes several promising drug candidates, with the CD40 agonist mitazalimab as its key asset. Furthermore, Alligator is co-developing ALG.APV-527 with Aptevo Therapeutics Inc., several undisclosed molecules based on its proprietary technology platform, Neo-X-Prime, and novel drug candidates based on the RUBY bispecific platform with Orion Corporation. Out-licensed programs include AC101/HLX22, in Phase 2 development, by Shanghai Henlius Biotech Inc. and an undisclosed target to Biotheus Inc.

Alligator Bioscience's shares are listed on Nasdaq Stockholm (ATORX) and is headquartered in Lund, Sweden.

For more information, please visit alligatorbioscience.com.

Attachments

Nomination Committee appointed in respect of AGM 2025 in Alligator Bioscience AB

SOURCE: Alligator Bioscience



View the original press release on accesswire.com

© 2024 ACCESSWIRE
Treibt Nvidias KI-Boom den Uranpreis?
In einer Welt, in der künstliche Intelligenz zunehmend zum Treiber technologischer Fortschritte wird, rückt auch der Energiebedarf, der für den Betrieb und die Weiterentwicklung von KI-Systemen erforderlich ist, in den Fokus.

Nvidia, ein Vorreiter auf dem Gebiet der KI, steht im Zentrum dieser Entwicklung. Mit steigender Nachfrage nach leistungsfähigeren KI-Anwendungen steigt auch der Bedarf an Energie. Uran, als Schlüsselkomponente für die Energiegewinnung in Kernkraftwerken, könnte dadurch einen neuen Stellenwert erhalten.

Dieser kostenlose Report beleuchtet, wie der KI-Boom potenziell den Uranmarkt beeinflusst und stellt drei aussichtsreiche Unternehmen vor, die von diesen Entwicklungen profitieren könnten und echtes Rallyepotenzial besitzen

Handeln Sie Jetzt!

Fordern Sie jetzt den brandneuen Spezialreport an und profitieren Sie von der steigenden Nachfrage, der den Uranpreis auf neue Höchststände treiben könnte.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.